8-KOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Dec 28, 2005)

Filed December 28, 2005For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) has announced the termination of its collaborative agreement with Merck & Co., Inc. for the investigational diabetes drug, muraglitazar. This termination, effective December 21, 2005, releases both parties from their prior obligations under the agreement, including standstill provisions. While specific financial details of the termination are not disclosed, the company stated that most obligations cease except for those arising from events prior to the termination date. This development signals a shift in BMY's diabetes drug pipeline and its strategic partnerships. Investors should note that the termination implies a re-evaluation of muraglitazar's commercial prospects or strategic fit for both companies. Further details regarding the original collaborative agreement were previously disclosed on a Form 8-K filed on May 10, 2004.

Key Highlights

  • 1Bristol-Myers Squibb (BMY) and Merck & Co., Inc. have mutually agreed to terminate their collaborative agreement for the investigational Type 2 diabetes drug, muraglitazar.
  • 2The termination agreement was reached on December 21, 2005, and is effective immediately.
  • 3All rights and obligations under the collaborative agreement, including standstill provisions, will cease to be in effect.
  • 4Exceptions to the termination of obligations apply only to events that occurred prior to the termination date.
  • 5The original terms of the collaborative agreement were previously disclosed on a Form 8-K filed on May 10, 2004.
  • 6A press release detailing this termination was issued on December 22, 2005, and is attached as an exhibit to this filing.

Frequently Asked Questions

The filing indicates a mutual agreement between Bristol-Myers Squibb and Merck & Co. to terminate the collaboration. Specific details on the underlying reasons for this mutual decision are not provided in this 8-K filing, but it implies a re-evaluation of the drug's prospects or strategic alignment.

Upon termination, Bristol-Myers Squibb retains the rights to muraglitazar, as the agreement was a collaboration. The termination agreement means that the collaboration with Merck is over, and Bristol-Myers Squibb will likely proceed with its development and commercialization plans independently or seek new partners.

The filing states that except for certain limited obligations arising from events that may have occurred prior to the termination date, all other rights and obligations under the collaborative agreement, including standstill provisions, will have no further force or effect. Specific financial implications of these pre-termination obligations are not detailed.

The immediate financial impact is not detailed in this 8-K. However, investors should monitor future earnings reports for any write-downs related to the muraglitazar asset or changes in R&D expenses. The termination suggests a potential shift in the company's diabetes drug strategy and pipeline focus.